AAV9: Over the fence and into the woods..

Molecular Therapy

Volumn 19, Issue 6, 2011, Pages 1006-1007

  Forsayeth, John R ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

AMYOTROPHIC LATERAL SCLEROSIS; ATAXIA; BLOOD BRAIN BARRIER; GENE EXPRESSION; HEMOPHILIA; NEUROPATHIC PAIN; NONHUMAN; NOTE; PARKINSON DISEASE; SPINAL CORD INJURY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS RECOMBINANT;

EID: 79957910863     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.95     Document Type: Note

References (18)

1. Pulicherla, N, Shen, S, Yadav, S, Debbink, K, Gov-indasamy, L, Agbandje-McKenna, M et al. (2011). Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 19: 1070-1078.
2. Kwon, I and Schaffer, DV (2008). Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 25: 489-499.
3. Work, LM, Nicklin, SA, Brain, NJ, Dishart, KL, Von Seggem, DJ, Hallek, M et al. (2004). Development of effcient viral vectors selective for vascular smooth muscle cells. Mol Ther 9: 198-208. (Pubitemid 38256546)
4. Gray, SJ, Matagne, V, Bachaboina, L, Yadav, S, Ojeda, SR, Samulski, RJ (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19: 1058-1069.
5. Kay, MA, Manno, CS, Ragni, MV, Larson, PJ, Couto, LB, McClelland, A et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261. (Pubitemid 30132193)
6. Fiandaca, M, Forsayeth, J and Bankiewicz, K (2008). Current status of gene therapy trials for Parkinson's disease. Exp Neurol 209: 51-57.
7. Gao, G, Vandenberghe, LH, Alvira, MR, Lu, Y, Calcedo, R, Zhou, X et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388. (Pubitemid 38715936)
8. Cearley, CN, Vandenberghe, LH, Parente, MK, Car-nish, ER, Wilson, JM and Wolfe, JH (2008). Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther 16: 1710-1718.
9. Manfredsson, F P, Rising, AC and Mandel, RJ (2009). AAV9: a potential blood-brain barrier buster. Mol Ther 17: 403-405.
10. Fu, H, DiRosario, J, Killedar, S, Zaraspe, K, McCarty, DM (2011). Correction of neurological disease of mucopoly-saccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 19: 1025-1033.
11. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astro-cytes. Nat Biotechnol 27: 59-65.
12. Su, X, Kells, A P, Huang, EJ, Lee, HS, Hadaczek, P, Bever, J et al. (2009). Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20: 1627-1640.
13. Manfredsson, F P, Tumer, N, Erdos, B, Landa, T, Broxson, CS, Sullivan, LF et al. (2009). Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 17: 980-991.
14. Boutin, S, Monteilhet, V, Veron, P, Leborgne, C, Benveniste, O, Montus, MF et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712.
15. Chirmule, N, Propert, K, Magosin, S, Qian, Y, Qian, R and Wilson, J (1999). Immune responses to adeno-virus and adeno-associated virus in humans. Gene Ther 6: 1574-1583. (Pubitemid 29465516)
16. Scallan, CD, Jiang, H, Liu, T, Patarroyo-White, S, Sommer, JM, Zhou, S et al. (2006). Human immuno-globulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107: 1810-1817. (Pubitemid 43289358)
17. Halbert, CL, Miller, AD, McNamara, S, Emerson, J, Gibson, RL, Ramsey, B et al. (2006). Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fbrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther 17: 440-447.
18. Virag, T, Cecchini, S and Kotin, RM (2009). Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther 20: 807-817.